# **Appendix 4E**

Preliminary final report for the twelve months to 30 June 2015

Name of entity MESOBLAST LIMITED ABN 68 109 431 870

### 1. Reporting period

| Report for the financial year ended                       | 30 June 2015 |
|---|--------------|
| Previous corresponding period is the financial year ended | 30 June 2014 |

### 2. Results for announcement to the market

|   | Up/down         | % change |    | Amount<br>reported for<br>the year ended<br>30 June 2015<br>\$000 |
|---|-----------------|----------|----|---|
| Revenues from ordinary activities (item 2.1)  | Up              | 14.7%    | to | 42,548  |
| Loss from ordinary activities after tax attributable to members ( <i>item 2.2</i> )   | Up <sup>*</sup> | 47.4%    | to | 119,368   |
| Net loss for the period attributable to members (item 2.3)  | Up <sup>*</sup> | 47.4%    | to | 119,368   |
| *increase in loss   |                 |          |    |   |
| There are no dividends being proposed or declared for the period (item 2.4 and 2.5)   |                 |          |    |   |
| Commentary related to the above results   |                 |          |    |   |
| Please refer to the Financial Review section of the Directors' Report within the Financial Report for the year ended 30 June 2015 and accompanying press release. |                 |          |    |   |

### 3. Net tangible assets per security

|   | 30 June 2015 | 30 June 2014 |
|---|--------------|--------------|
| Net tangible asset/(liability) backing<br>per ordinary security | 22.80 cents  | 40.00 cents  |

A large proportion of the company's assets are intangible in nature, consisting of intellectual property and goodwill relating to the acquisition of Mesoblast, Inc and culture-expanded Mesenchymal Stem Cells (ceMSCs) technology. These assets and the associated provision for contingent consideration are excluded from the calculation of net tangible assets per security. A deferred tax liability of \$194,514k has also been excluded from the calculation to the extent it relates to future tax obligations as a result of the intellectual property assets deriving revenue at some point in the future. This deferred tax liability has arisen as a direct result of the intellectual property being acquired.

## 4. Other documents accompanying this Appendix 4E

A copy of the audited Financial Report and Directors' Report for the year ending 30 June 2015 for the Mesoblast Group is attached and should be read in conjunction with this Appendix 4E.

#### 5. Audited Financial Report 2015

This report has been based on accounts which have been audited. A copy of the audited Financial Report and Directors' Report for the year ended 30 June 2015 is attached to this report.